Lobe Sciences Ltd has announced the development of its initial Phase 1 study plan to demonstrate the safety and appropriate dosing range for its proprietary.
Lobe Sciences Ltd has announced the development of its initial Phase 1 study plan to demonstrate the safety and appropriate dosing range for its proprietary.
Virtual Investor Conferences (VIC), the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the.